Stay updated on Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page.

Latest updates to the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedFooter shows Revision: v3.3.3, and the HHS Vulnerability Disclosure link along with Revision: v3.3.2 have been removed.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedRevision: v3.3.2 replaces v3.3.1 on the page, a minor metadata update that does not affect study details or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision metadata on the page was updated from v3.2.0 to v3.3.1, with no changes to the study content or critical information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedThe government funding status notice was removed from the page; core study details and contact information remain unchanged.SummaryDifference0.4%

- Check70 days agoChange DetectedNo meaningful changes detected on the page; the study details appear unchanged.SummaryDifference0.5%

- Check98 days agoChange DetectedAdded a government funding lapse notice and updated version to v3.2.0; removed the previous v3.1.0 tag.SummaryDifference2%

Stay in the know with updates to Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page.